Rapport Therapeutics (RAPP) Set to Announce Quarterly Earnings on Thursday

Rapport Therapeutics (NASDAQ:RAPP) is expected to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($1.20) per share for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 6, 2026 at 9:30 AM ET.

Rapport Therapeutics (NASDAQ:RAPP) last announced its earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.07). On average, analysts expect Rapport Therapeutics to post ($4.08) EPS for the current fiscal year and ($5.05) EPS for the next fiscal year.

Rapport Therapeutics Price Performance

Shares of NASDAQ RAPP opened at $22.50 on Thursday. Rapport Therapeutics has a 12-month low of $22.06 and a 12-month high of $52.93. The company has a market capitalization of $1.08 billion, a PE ratio of -7.40 and a beta of 1.22. The firm’s 50-day moving average is $37.66 and its two-hundred day moving average is $35.61.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on RAPP shares. JonesTrading raised their price objective on shares of Rapport Therapeutics from $50.00 to $82.00 and gave the stock a “buy” rating in a research note on Wednesday, October 21st. Wall Street Zen downgraded Rapport Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rapport Therapeutics in a research note on Thursday, October 15th. Guggenheim upped their target price on Rapport Therapeutics from $65.00 to $70.00 and gave the company a “buy” rating in a research note on Tuesday, October 20th. Finally, BTIG Research increased their target price on Rapport Therapeutics from $75.00 to $89.00 and gave the company a “buy” rating in a report on Tuesday, October 20th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $68.36.

Insider Transactions at Rapport Therapeutics

In other Rapport Therapeutics news, COO Cheryl Gault sold 10,000 shares of the company’s stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $33.19, for a total value of $331,900.00. Following the transaction, the chief operating officer directly owned 139,914 shares in the company, valued at approximately $4,643,745.66. This represents a 6.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Steven M. Paul bought 35,714 shares of Rapport Therapeutics stock in a transaction on Thursday, October 22nd. The stock was purchased at an average price of $27.28 per share, for a total transaction of $974,277.92. Following the completion of the acquisition, the director owned 77,380 shares in the company, valued at $2,110,926.40. This represents a 85.71% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have acquired 61,694 shares of company stock worth $1,664,818 and have sold 97,976 shares worth $4,391,729. Company insiders own 12.48% of the company’s stock.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.